MedPath

Evaluation of The Effect of N-acetylcysteine in The Prevention of Vancomycin-Induced Renal Disorder

Phase 3
Conditions
Vancomycin-Induced Nephrotoxicity.
Registration Number
IRCT20150721023282N3
Lead Sponsor
Esfahan University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

Treatment with Vancomycin for at Least 5 Days
Creatinine Clearance > 60 ml/min (Based on MDRD Formula)

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Serum Creatinine. Timepoint: At baseline and 2, 4, 6, 8, and 10 days after initiation of intervention. Method of measurement: Spectrophotometry.;Blood Urea Nitrogen. Timepoint: At baseline and 2, 4, 6, 8, and 10 days after initiation of intervention. Method of measurement: Spectrophotometry.;Creatinine Clearance. Timepoint: At baseline and 2, 4, 6, 8, and 10 days after initiation of intervention. Method of measurement: Cockroft - Gault Formula.;12-hour Urine Volume. Timepoint: At baseline and 2, 4, 6, 8, and 10 days after initiation of intervention. Method of measurement: Urine Bag.;The number of patients with acute kidney injury. Timepoint: End of intervention. Method of measurement: counting.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath